Neurogene Inc
NASDAQ:NGNE

Watchlist Manager
Neurogene Inc Logo
Neurogene Inc
NASDAQ:NGNE
Watchlist
Price: 18.8 USD 10.91%
Market Cap: 291.2m USD

Neurogene Inc
Cash from Financing Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neurogene Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Neurogene Inc
NASDAQ:NGNE
Cash from Financing Activities
$199.8m
CAGR 3-Years
828%
CAGR 5-Years
5%
CAGR 10-Years
8%
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$15.4B
CAGR 3-Years
10%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$4.2B
CAGR 3-Years
15%
CAGR 5-Years
-75%
CAGR 10-Years
-37%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$11B
CAGR 3-Years
-5%
CAGR 5-Years
-28%
CAGR 10-Years
-7%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$2.6B
CAGR 3-Years
-80%
CAGR 5-Years
-64%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$4.1B
CAGR 3-Years
-35%
CAGR 5-Years
-15%
CAGR 10-Years
-23%
No Stocks Found

Neurogene Inc
Glance View

Market Cap
277.8m USD
Industry
Biotechnology

Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.

NGNE Intrinsic Value
17.13 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Neurogene Inc's Cash from Financing Activities?
Cash from Financing Activities
199.8m USD

Based on the financial report for Sep 30, 2025, Neurogene Inc's Cash from Financing Activities amounts to 199.8m USD.

What is Neurogene Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
8%

Over the last year, the Cash from Financing Activities growth was 130%. The average annual Cash from Financing Activities growth rates for Neurogene Inc have been 828% over the past three years , 5% over the past five years , and 8% over the past ten years .

Back to Top